All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): UV1,GM-CSF,Pembrolizumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2020
Details:
The FOCUS (First-line metastatic Or recurrent HNSCC/Checkpoint inhibitor UV1 Study) Phase II trial will evaluate the addition of UV1 to a standard of care treatment with PD-1 checkpoint inhibitor pembrolizumab as compared to pembrolizumab monotherapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bemcentinib,Cytarabine
Therapeutic Area: Oncology Product Name: BGB 324
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2020
Details:
The data indicates that treatment with the bemcentinib-LDAC combination shows promising efficacy in relapsed patients who are unfit for intensive chemotherapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Fimaporfin,Gemcitabine Hydrochloride,Cisplatin
Therapeutic Area: Oncology Product Name: Amphinex
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
The European patent covers the intended use of fimaChem in combination with gemcitabine for the treatment of cholangiocarcinoma (bile duct cancer).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bemcentinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: BGB324
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
Details:
The combination of bemcentinib and pembrolizumab was overall shown to be well tolerated and clinically active in CPI-refractory composite AXL (cAXL) positive NSCLC.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VB10.NEO
Therapeutic Area: Oncology Product Name: VB10.NEO
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Genentech
Deal Size: $715.0 million Upfront Cash: $200.0 million
Deal Type: Collaboration November 06, 2020
Details:
Announced on October 1, 2020 the deal is now effective with the expiration of the HSR Act waiting period. Under the agreement, Genentech and Vaccibody will progress Vaccibody’s investigational product candidate, VB10.NEO, into clinical trials in the U.S. and in Europe.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VB10.NEO
Therapeutic Area: Oncology Product Name: VB10.NEO
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Genentech
Deal Size: $715.0 million Upfront Cash: $200.0 million
Deal Type: Collaboration October 01, 2020
Details:
The agreements aims to develop and commercialize DNA-based individualized neoantigen vaccines for the treatment of cancers. Vaccibody will conduct development through the end of Phase 1b and Genentech will be responsible for development and commercialization thereafter.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Fimaporfin,Gemcitabine Hydrochloride
Therapeutic Area: Oncology Product Name: Amphinex
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2020
Details:
PCI Biotech has announced case report series from the Phase I study with PCI Biotech's proprietary drug fimaporfin (AmphinexTM), for the treatment of inoperable extrahepatic bile duct cancer (eCCA), is accepted for publishing in Endoscopy International Open.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lutetium (177Lu)-lilotomab satetraxetan
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2020
Details:
PARADIGME is the company's ongoing global, randomised Phase 2b trial investigating Betalutin® (177Lu-lilotomab satetraxetan) as a single administration in patients with 3rd-line relapsed / anti-CD-20-refractory FL who have received two or more prior therapies (3L R/R FL).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bemcentinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2020
Details:
The presentation to be given will provide an update of results from a phase II trial, evaluating bemcentinib in combination with MSD’s Keytruda in previously treated non-small cell lung cancer (NSCLC) patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lutetium (177Lu)-lilotomab satetraxetan
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2020
Details:
Streamlined strategy with all resources focused on PARADIGME- all other trials to be suspended following completion of the current cohorts and all investments in pre-clinical assets to be halted.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
